Sage Therapeutics’ stock plunges as Parkinson’s drug trial disappoints

Sage Therapeutics shares dropped early Wednesday after the company said its experimental treatment for mild cognitive impairment in patients with Parkinson’s disease fell flat in a clinical trial.

Previous post Children’s Place’s stock soars 36% after retailer gets new $90 million loan from Saudi investor Mithaq Capital
Next post Most doses of Eli Lilly’s Zepbound, Mounjaro in short supply through June, FDA says